**Summary**
Oxford Biomedica PLC (OXB) has signed a new multi-year Commercial Supply Agreement (CSA) with Bristol Myers Squibb (BMS) to manufacture and supply lentiviral vectors for BMS’s CAR-T cell therapy programs. This agreement, announced on February 4, 2026, expands their existing partnership established in March 2020. The five-year initial term includes an option to extend, with commercial manufacturing expected to begin in 2026, pending regulatory approval of the CAR-T products. Manufacturing will take place at OXB’s facilities in Oxford, UK, and Durham, NC, USA.
The CSA is projected to generate significant multi-year revenue, supporting OXB’s medium-term financial goals and reinforcing its position as a leading cell and gene therapy CDMO. Dr. Sebastien Ribault, OXB’s Chief Business Officer, highlighted the milestone as a transition from clinical to commercial manufacturing, emphasizing confidence in the partnership and the company’s strategic execution. Chris Holt of BMS praised OXB’s expertise and reliability in delivering high-quality viral vectors, ensuring scalable manufacturing capacity for BMS’s innovative CAR-T therapies.
OXB, a FTSE250 and FTSE4Good constituent, has 30 years of experience in viral vector development and manufacturing, collaborating with global pharmaceutical and biotech leaders. This agreement underscores OXB’s commitment to enabling life-changing therapies and its strong track record in the cell and gene therapy sector.